

What is claimed is:

1. A method of inducing an antiviral response in an individual comprising administering to the individual an effective amount of an agent which blocks the binding of lymphotoxin- β to its receptor, and a pharmaceutically acceptable carrier.
- 5 2. A method of claim 1 wherein said agent is a LT-beta-R blocking agent.
3. The method of claim 2 wherein said agent is an antibody against the lymphotoxin- β receptor or a soluble lymphotoxin- β receptor.
4. The method of claim 3 wherein said agent is a lymphotoxin- β receptor/Ig fusion protein.
- 10 5. The method of claim 1 wherein said agent is a soluble lymphotoxin- β or an antibody against lymphotoxin- β .
6. A method of inducing an antiviral response in an individual comprising administering to the individual an effective amount of an agent which blocks the lymphotoxin- β -receptor and/or HVEM signaling pathway.
- 15 7. The method of claims 1- 6 wherein said individual is infected with Sin Nombre Virus, Ebola virus, Marburg virus, Lassa virus or Dengue.
8. The method of claim 7 wherein the agent is a lymphotoxin- β -R/Ig fusion protein.